Hard to Treat Diseases, Inc. (HTDS) Reports on Beneficial Effects of Treatment with Combination of B Vitamins on Recovery from Brain Trauma

BELGRADE, Serbia, May 18 /PRNewswire-FirstCall/ – Hard to Treat Diseases, Inc. (HTDS:PK), http://www.htdsmedical.com is pleased to announce the second poster presentation researchers from its Slavica BioChem (www.slavicabiochem.com) division have presented at the 8th World Congress on the Brain Injury, held in Washington, DC, March 10-14, 2010, under the auspices of The International Brain Injury Association (IBIA) http://www.internationalbrain.org/. The Slavica team presented results which show the potential beneficial effects of repetitive treatment with the cocktail of B vitamins (B1, B2, B3, B6, and B12) on recovery after traumatic brain injury. The IBIA World Congress is the largest gathering of international professionals working in the field of brain injury. Experts of different background took part in this Congress: scientists, physicians, psychologists and neuropsychologists, therapists, social workers, nurses and other professionals involved in the field of brain injury. The Organizers reported the 2010 Meeting was the largest IBIA meeting ever organized, with more than 1000 participants and over 650 accepted abstracts.

Prof Mirjana Stojiljkovic, the leader of Slavica BioChem research team said: “As Dr Pekovic in previous press release (April 6, 2010) mentioned this Congress was an excellent opportunity to get insight into the state-of-the-art research, from the basic science to the clinical aspects of brain injury, as well as for establishing important contacts with international professionals involved in the brain injury research and the care of people with acquired brain injury. At the same time, we were able to present our results in a summary Poster format which was available for review by attendees. We had 3h long session with the visitors of our poster presentation discussing all the questions on the topic presented. Since our results belong to the basic science and are focused to cellular mechanisms underlying traumatic brain injury (TBI) they were very attractive for the numerous medical doctors attending the Congress. Namely, despite all efforts TBI continues to pose a significant health care risk for which there is currently no effective treatment. For many years we are looking for the approaches that could improve recovery after TBI. In this study we focused our attention to B vitamins.”

Prof. Mirjana Stojiljkovic added: “Most importantly, the results of our behavioral studies indicated that repetitive treatment with the cocktail of B vitamins (B1, B2, B3, B6, and B12), significantly improved motor coordination of movement. Looking for the effects at the cellular level we observed that B vitamins could induce reduction of glial scar that has been considered as one of the major impediments to neuronal regeneration.”

In summary, Prof. Mirjana Stojiljkovic concluded: “These findings are encouraging, they expand and further validate the use of B vitamins as a potentially effective treatment that should be seriously considered for clinical trials in TBI.”

For any matters relating to retail investor queries or to send the company or its IR a message please click on the “INVESTOR SUPPORT” TAB, or the direct link http://www.minamargroup.net/helpdesk.

Don’t be a victim. Report a stock basher. The company is mindful that short sellers, the company competitors and stock bashers stalk small cap Pink Sheets listed companies with hidden agendas. Visit http://www.stockbasher.com/ and find out what criminal and civil actions the US authorities are taking against web sites like investorshub.com and other posters, and the remedies available to you as an individual investor.

Filings for this event are currently being reviewed and will be filed with Pink Sheets and Client Support section in due course. To be included in company’s email database for press releases, industry updates, and non-weekly activity in the company that may or may not be news released, please subscribe or opt in mailer at http://www.minamargroup.com/updates.

Safe Harbor Statement

Information in this filing may contain statements about future expectations, plans, prospects or performance of Hard to Treat Diseases, Inc. that constitute forward-looking statements for purposes of the safe harbor Provisions under the Private Securities Litigation Reform Act of 1995. The words or phrases “can be,” “expects,” “may affect,” “believed,” “estimate,” “project,” and similar words and phrases are intended to identify such forward-looking statements. HTDS Corporation cautions you that any forward-looking information provided by or on behalf of Hard to Treat Diseases, Inc. is not a guarantee of future performance. None of the information in this filing constitutes or is intended as an offer to sell securities or investment advice of any kind. Hard to Treat Diseases, Inc.’s actual results may differ materially from those anticipated in such forward-looking statements as a result of various important factors, some of which are beyond Hard to Treat Diseases, Inc.’s control. In addition to those discussed in Hard to Treat Diseases, Inc.’s press releases, public filings, and statements by Hard to Treat Diseases, Inc.’s management, including, but not limited to, Hard to Treat Diseases, Inc.’s estimate of the sufficiency of its existing capital resources, Hard to Treat Diseases, Inc.’s ability to raise additional capital to fund future operations, HTDS Corporation’s ability to repay its existing indebtedness, the uncertainties involved in estimating market opportunities and, in identifying contracts which match Hard to Treat Diseases, Inc.’s capability to be awarded contracts. All such forward-looking statements are current only as of the date on which such statements were made. Hard to Treat Diseases, Inc. does not undertake any obligation to publicly update any forward-looking statement to reflect events or circumstances after the date on which any such statement is made or to reflect the occurrence of unanticipated events.

CONTACT: www.minamargroup.com/helpdesk

SOURCE Hard to Treat Diseases